Analyst Ratings For Arcturus Therapeutics (NASDAQ:ARCT)
Today, Chardan Capital initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy with a price target of $12.00.
Some recent analyst ratings include
- 1/22/2018-Chardan Capital initiated coverage with a Buy rating.
- 11/29/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 10/9/2017-WBB Securities Upgrade from a “Hold ” rating to a ” Buy” rating.
- 9/29/2017-Roth Capital was Downgraded by analysts at Roth Capital from a “Buy ” rating to a ” Neutral” rating. They now have a $1.00 price target on the stock, up previously from $4.00 .
- 6/12/2017-Jefferies Group Reiterated Rating of Hold.
- 4/13/2017-Cantor Fitzgerald Reiterated Rating of Hold.
Recent Trading Activity for Arcturus Therapeutics (NASDAQ:ARCT)
Shares of Arcturus Therapeutics closed the previous trading session at 9.39 up +0.24 2.62% with 6636 shares trading hands.
